全球血管支架市場：市場規模、佔有率和趨勢分析（2025-2031 年）

全球血管支架市場報告

2025年全球血管支架市場規模為29億美元。在預測期內，該市場預計將以4.9%的複合年成長率成長，到2032年將達到41億美元。

• 這份關於全球血管支架市場的綜合報告涵蓋七個區域：北美、拉丁美洲、西歐、中東歐、中東、亞太地區和非洲。報告針對每個區域提供市場規模、銷售分析和平均售價數據，並預測至2032年，清楚展現未來市場趨勢與成長模式。本報告遵循與附件範例文件相同的結構和最佳實踐流程，並針對血管支架市場及其特定的競爭格局和臨床趨勢進行了客製化。

本報告對全球血管支架市場進行了詳細分析，包括截至 2022 年的歷史數據，以及銷售量、手術量、平均售價、市場佔有率、市場規模、成長趨勢和截至 2032 年的市場預測。報告還包括對近期併購、公司簡介、產品系列、主要企業以及影響市場擴張的主要因素的定性分析。

推動這一市場發展的動力源於人們對微創血管治療的持續需求。由於與開放性手術相比，血管內修復能夠減輕患者負擔、縮短住院時間並加快康復，因此在許多主動脈手術中，血管內修復正日益成為首選。這種轉變促使支架血管支架在腹部主動脈血管瘤修復、胸主動脈血管內修復以及以往微創治療選擇有限的更複雜解剖結構中得到更廣泛的應用。

總體而言，全球血管支架市場仍然是血管介入領域最重要的成長領域之一。推動該市場成長的因素包括：顯著的臨床需求、強勁的創新能力、不斷擴大的篩檢活動以及微創主動脈修復技術的持續發展。

市場概覽

全球血管支架市場包括用於阻塞動脈瘤和修復主動脈及相關血管結構病變的植入式血管內裝置，無需開放性手術。這些裝置最常用於腹部主動脈血管瘤、胸主動脈瘤以及複雜或解剖結構異常的修復手術。它們是血管疾病血管內治療這一大趨勢的重要組成部分。

隨著醫生和醫療系統越來越傾向於在臨床上適宜的情況下採用微創治療方案，這一市場應運而生。與傳統外科手術相比，血管內血管支架可縮短手術時間、減少出血量、縮短住院時間並加速患者復原。這些優點使得血管支架成為許多高風險、難以耐受開放性手術患者的重要選擇。

血管支架市場也反映了血管介入治療技術的日益複雜化。早期產品的解剖適用範圍有限，柔軟性也較差。如今，製造商正致力於研發能夠更好地應對複雜解剖結構、更嚴格的入路條件以及更專業化手術需求的移植物設計。這包括持續開發胸腔、開窗和分支型技術，以及改善輸送系統，從而簡化醫生的操作流程。

因此，儘管市場在某些領域，特別是標準腹部修復領域，已經趨於成熟，但隨著新技術的引入、篩檢的改進、醫生接受度的提高以及針對複雜病例的治療方案的拓展，市場仍在持續成長。這種既定的臨床需求與持續創新之間的平衡，正是市場預計到2032年將穩定成長的主要原因。

市場促進因素

TAA血管支架

全球血管支架市場最重要的促進因素之一是胸主動脈瘤血管支架的成長潛力。與某些腹部應用相比，胸主動脈段是一個相對較新的領域，仍有很大的發展空間。如果夾層、潰瘍和創傷等適應症繼續納入治療方案，未來胸主動脈段支架移植物可望佔更大的市場佔有率。

未經治療的胸主動脈瘤風險極高，因此該領域存在著巨大的臨床需求。過去，由於手術方案複雜且風險高，相當一部分胸主動脈瘤患者未能接受治療。隨著經皮腔內經皮修復術（TAA）的日益成熟和器械設計的不斷改進，越來越多的患者符合微創治療的條件。這直接推動了對TAA血管支架日益成長的需求。

產品研發的進一步發展也推動了該領域的擴張。低輪廓器械、更高的柔軟性、更強的反應速度以及分支型胸腔平台，都在拓展可用於血管內治療的解剖結構範圍。這些改進促進了銷售額的成長和市場價值的提升。

長期成本效益

另一個主要的市場促進因素是血管支架手術的長期成本效益。雖然血管支架本身比外科移植更昂貴，但由於其通常能縮短患者的住院時間，因此總體經濟價值仍然很有吸引力。對於患者周轉率率高或床位緊張的醫院來說，這是一個顯著的優勢。

開放性手術，尤其是在出現併發症的情況下，會導致更長的恢復期和更耗費醫療資源的住院治療。雖然血管支架的初始成本較高，但住院時間的縮短可以抵消部分成本。這種價值提案正在推動許多已開發市場採用支架移植術，並且仍然是血管支架商業性應用的關鍵因素。

擴大動脈瘤篩檢

動脈瘤篩檢的普及也推動了市場成長。在一些地區，尤其是在歐洲部分地區，血管內治療的普及率與其他已開發市場相比仍然較低。然而，加強篩檢有望更早發現更多動脈瘤患者，從而擴大符合診斷條件的患者群體，並最終增加未來的治療數量。

在英國等國家，篩檢工作正在加強，部分原因是人口老化導致動脈瘤盛行率預計上升。隨著確診患者數量的增加，更多患者將進入治療流程，並考慮接受血管支架移植手術。這使得篩檢成為推動市場長期發展的重要因素。

市場限制

解剖學上的困難

全球血管支架市場最大的限制因素是解剖結構的複雜性。血管支架手術的成功很大程度上取決於精細的影像檢查、精確的尺寸選擇以及器械設計與患者解剖結構的匹配度。並非所有患者的解剖條件都適合進行標準的腹部或胸部血管內修復手術。

頸部解剖結構異常、血管彎曲、分支受累以及其他結構性挑戰會限制血管支架手術的可行性。雖然模組化移植物系統以及新型開窗和分支設計擴大了可治療的患者範圍，但仍有相當一部分患者需要進行開放手術修復，例如當血管內治療在解剖結構上不可行，或由於破裂風險而沒有足夠的時間採取更個性化的治療方案時。

這項限制尤其重要，因為僅靠標準設備就足以限制市場成長。儘管創新不斷提升這一上限，但解剖學因素仍是限制市場發展的關鍵因素。

血管支架併發症

血管支架的併發症也持續限制市場擴張。與開放性手術相比，血管內動脈瘤修復術（EVAR）的長期再介入風險可能更高。包括DREAM試驗在內的一些臨床試驗表明，EVAR與較高的再干涉率有關，這正在影響醫生的理念和長期追蹤實踐。

此外，血管支架植入術後動脈瘤破裂的風險也令人擔憂。如果血管閉塞不完全或支架的長期性能受損，這種擔憂尤其突出。雖然這些擔憂並未否定血管支架的吸引力，但卻凸顯了後續影像檢查和後續觀察的重要性。在某些醫療體系中，這可能會削弱支架移植術經濟效益的顯而易見性，並影響醫師對病患的選擇。

高級病例的複雜性

另一個阻礙因素是高階血管支架手術的複雜性。雖然開窗支架血管支架和胸主動脈血管支架術具有很高的臨床價值，但它們需要更細緻的術前計劃、更專業的影像檢查和更高的技術水平。這可能限制了此類手術的開展，尤其是在高級血管內治療基礎設施不完善的地區，只有病例量大且經驗豐富的外科醫生才能進行此類手術。

因此，高階細分市場的市場成長可能強勁，但其分佈並不均衡。產品的普及不僅取決於臨床需求，還取決於醫生的訓練程度和醫療機構的能力。

市場覆蓋範圍和數據範圍

定量範圍

市場規模、市佔率、市場預測、市場成長率、銷售量、平均售價。

定性範圍

市場促進因素和限制因素、成長趨勢、近期併購、公司概況、產品系列和主要競爭對手。

目標期

基準年：2025 年，歷史資料：截至 2022 年，預測：截至 2032 年。

按地區定位

北美洲、拉丁美洲、西歐、中歐和東歐、中東、亞太地區、非洲。

包含的資料類型

銷售量、平均售價、治療次數、市場規模和成長趨勢。

本報告旨在透過將詳細的預測與可操作的臨床和商業性背景相結合，為策略規劃、競爭對手基準分析和產品定位提供支援。

目標市場及區隔

• 本報告涵蓋全球血管支架市場，並進一步細分為以下幾類：

AAA血管支架市場

此部分包括用於腹部主動脈血管瘤修復的裝置，也包括標準 EVAR 手術中使用的關鍵組件類別。

開窗支架血管支架市場

該部分包括專為更複雜的解剖結構設計的高級移植系統，在這些系統中，保留分支血管和客製化密封至關重要。

TAA血管支架市場

此部分包括用於 TEVAR（經皮皮胸主動脈瘤治療）和其他胸主動脈介入治療的胸主動脈血管支架。

每個細分市場均根據銷售量、平均售價和總市場價值進行分析，並包括截至 2032 年的預測和截至 2022 年的歷史數據。這種細分反映了血管內移植物技術持續擴展的關鍵臨床應用領域。

競爭分析

戈爾公司在腹部主動脈血管瘤市場的多個細分領域佔主導地位，包括分叉支架、對側和同側髂嵴支架以及髂動脈延伸支架。該公司在主動脈延伸支架領域也保持著穩固的第二名地位。雖然該公司不提供主動脈-單側髂動脈血管支架，但其廣泛的腹主動脈瘤產品組合仍具有很高的影響力。監管方面的里程碑事件進一步鞏固了其市場地位。 「GORE EXCLUDER 髂動脈分支系統」於 2016 年獲得 FDA核准，「GORE TAG 胸主動脈分支血管支架」於 2022 年獲得 FDA核准，用於需要進行左鎖骨下動脈分叉清創的高風險患者。戈爾公司還獲得了具有「主動控制」功能的「TAG 可塑性胸主動脈支架系統」的核准，該功能有助於在胸主動脈腔內修復術 (TEVAR) 中更好地控制支架的展開和密封。

美敦力憑藉其Endurant II腹主動脈瘤（AAA）產品組合和Valiant胸主動脈血管支架（EVAR）和胸主動脈腔內血管修復術（TEVAR）領域的地位，並推出了Heli-FX和Heli-FX胸主動脈內錨定系統。此外，美敦力也透過獲得FDA核准Valiant Navion胸主動脈血管支架系統，並隨後將Valiant系列擴展到胸腹主動脈應用，進一步加強了其在高級主動脈修復領域的地位。

庫克醫療憑藉其豐富的腹部主動脈血管瘤(AAA) 和胸主動脈產品產品系列，依然保持著領先地位。其 Zenith Flex 和 Zenith Renu 系列產品在標準腹部組件領域佔重要地位，尤其在開窗式腹主動脈支架領域，Zenith Fenestrated 系列產品表現突出。儘管該產品系列可能因評估複雜、等待時間長和成本高而限制了其市場普及，但多年來仍保持了強勁的銷售成長。在胸主動脈修復領域，庫克醫療銷售的 Zenith Alpha 系列產品已獲得 FDA核准，用於治療孤立性降主動脈病變。庫克醫療相對較低的平均單例售價 (ASP) 也鞏固了其市場地位，尤其是在對價格要求較高的市場。

總體而言，競爭格局由產品的廣度、監管進步、解剖學適用性以及支持日益複雜的血管內修復手術的能力所決定。

科技和醫療治療的發展趨勢

全球血管支架市場的一大趨勢是持續向微創主動脈修復方向轉變。當患者的解剖結構和臨床狀況允許時，醫生越來越傾向於採用血管內治療方法。

另一個重要趨勢是更先進的血管支架技術的發展。低輪廓裝置、更高的柔軟性、更強的貼合性以及更專業的分支和開窗系統，使得在更廣泛的解剖結構中進行治療成為可能。

診斷影像和導航的重要性也日益凸顯。術前計畫的準確性提高和手術執行的精準性增強，能夠改善治療效果，並降低併發症和再次手術的風險。

最後，市場正朝著更貼合解剖特徵的治療方案轉變。雖然標準器材仍然重要，但針對複雜解剖結構和高風險患者群體設計的更專業的血管支架正日益成為推動市場成長的主要動力。

地區

本報告提供了涵蓋北美、歐洲、亞太地區、拉丁美洲以及中東和非洲的全球研究成果。

報告包含詳細的市場分析、區域洞察和預測數據，共 109 頁。

附錄：調查方法和縮寫詞彙表。

這份報告的意義

到 2032 年，全球血管支架市場中最大、成長最快的機會在哪裡？

胸腔和開窗技術如何改變市場的價值結構？

篩檢計畫和對微創治療的偏好將在未來的成長中發揮什麼作用？

解剖學上的挑戰和再次干預的風險如何限制血管支架的潛在市場規模？

在 AAA、開窗式和 TAA血管支架領域，哪些公司擁有最強的地位，它們之間又是如何競爭的？

供應商如何調整其產品策略，以滿足對更精準、更符合解剖結構的血管內修復技術日益成長的需求？

iData Research 的「全球血管支架市場報告」透過詳細的市場區隔、定價分析、競爭格局資訊和市場預測，解答了這些問題。利用這份報告，您可以將貴公司與競爭對手進行比較，評估成長機會，並在血管介入器械這一關鍵領域制定策略。

目錄

圖表清單

調查方法

• 步驟 1：計劃啟動與團隊組建
• 步驟 2：準備資料系統並進行二次調查。
• 步驟 3：設計和準備訪談和調查問卷。
• 步驟 4：進行初步調查
• 步驟 5：調查與分析：建立基準估計值
• 步驟 6：市場預測與分析
• 步驟 7：辨識策略機遇
• 步驟 8：最終審核和市場推廣
• 步驟 9：客戶回饋與市場監測

全球關稅的影響

血管支架市場

• 摘要整理
  • 全球血管支架市場概覽
  • 競爭分析
  • 目標程式
  • 目標市場
  • 目標區域
• 介紹
• 手術次數
  • 整體血管支架手術
  • AAA血管支架手術
  • 開窗支架血管支架手術
  • TAA血管支架手術
• 市場概覽
  • 按細分市場
  • 按地區
• 市場分析與預測
  • 血管支架市場整體狀況
  • AAA血管支架市場
  • 開窗支架血管支架市場
  • Taa血管支架市場
• 促進因素和抑制因素
• 競爭性市佔率分析

簡稱

Global Stent Graft Market Report

The global stent graft market was valued at $2.9 billion in 2025. Over the forecast period, the market is expected to grow at a CAGR of 4.9% to reach $4.1 billion by 2032.

• The full report suite on the global market for stent grafts covers seven geographical regions: North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Asia-Pacific and Africa. For each region, the report provides market valuation, unit analysis and average selling price data, while also extending projections through 2032 to provide a clear view of future market trends and growth patterns. This description follows the same structure and best-practice flow used in the attached example document, adapted to the stent graft market and its specific competitive and clinical dynamics .

This report provides detailed analysis of the global stent graft market, including unit sales, procedure numbers, average selling prices, market shares, market size, growth trends and market forecasts through 2032, with historical data to 2022. It also includes recent mergers and acquisitions, company profiles, product portfolios, leading competitors, and qualitative analysis of the main forces shaping market expansion.

The market is being supported by the continued shift toward minimally invasive vascular treatment. Endovascular repair is increasingly preferred in many aortic procedures because it can reduce patient trauma, shorten hospital stays and support faster recovery when compared with open surgery. This shift is encouraging broader use of stent grafts in abdominal aortic aneurysm repair, thoracic endovascular aortic repair and more complex anatomies that previously had fewer minimally invasive treatment options.

Overall, the global stent graft market remains one of the more important growth areas in vascular intervention. It combines a large installed clinical need with strong innovation, expanding screening activity and continued movement toward less invasive aortic repair.

Market Overview

The global stent graft market includes implantable endovascular devices used to exclude aneurysms and repair diseased sections of the aorta and related vascular anatomy without requiring full open surgery. These devices are used most prominently in abdominal aortic aneurysm, thoracic aortic aneurysm and fenestrated or anatomically complex repair procedures. They represent a key part of the broader trend toward endovascular management of vascular disease.

This market has developed as physicians and healthcare systems increasingly favor less invasive treatment pathways where clinically appropriate. Compared with traditional surgical graft implantation, endovascular stent graft procedures can reduce operating time, limit blood loss, shorten hospital stays and support faster patient recovery. These advantages have made stent grafts an important option in many high-risk patients who may not tolerate open surgery as well.

The stent graft market also reflects the growing sophistication of vascular intervention. Earlier generations of devices had more limited anatomical applicability and lower flexibility. Today, manufacturers are investing in graft designs that can better accommodate difficult anatomies, more challenging access conditions and more specialized procedural needs. This includes ongoing development in thoracic, fenestrated and branched technologies, as well as improvements in delivery systems that make the procedure more manageable for physicians.

The result is a market that is mature in some areas, especially standard abdominal repair, but still expanding through newer technologies, improved screening, broader physician adoption and better treatment options for complex cases. This balance of established clinical need and continuing innovation is a major reason why the market is expected to grow steadily through 2032.

Market Drivers

TAA Stent Grafts

One of the most important drivers in the global stent graft market is the growth potential of thoracic aortic aneurysm stent grafts. The thoracic segment remains relatively newer than some abdominal applications and still has meaningful room for expansion. If indications such as dissections, ulcers and trauma continue to be incorporated into treatment pathways, the thoracic segment could represent a much larger share of the total market over time.

There is strong clinical demand in this segment because untreated thoracic aortic aneurysms carry a high risk. A meaningful proportion of thoracic patients historically went untreated because the surgical option was complex and risky. As thoracic endovascular aortic repair becomes more established and device design improves, more patients can be considered for minimally invasive treatment. This directly supports growth in TAA stent graft demand.

Further product development is also helping expand this segment. Lower-profile devices, better flexibility, improved trackability and branched thoracic platforms all increase the number of anatomies that can be treated endovascularly. These improvements support both unit growth and higher market value.

Long-Term Cost Efficiency

Another major market driver is the long-term cost efficiency of stent graft procedures. Although stent grafts are more expensive than surgical grafts at the device level, their overall economic value can still be attractive because patients often require shorter hospital stays. For hospitals with high patient turnover or pressure on inpatient capacity, this is an important advantage.

Open surgery can lead to longer recoveries and more resource-intensive hospital stays, especially when complications occur. Even when a stent graft has a higher initial price, the ability to reduce hospitalization time can offset part of that cost. This value proposition has helped support adoption in many developed markets and remains an important part of the commercial case for stent graft use.

Increased Aneurysm Screening

Greater aneurysm screening is also supporting market expansion. In some regions, especially parts of Europe, endovascular penetration rates remain lower than in other developed markets. However, efforts to increase screening are expected to identify more aneurysm patients earlier, which expands the diagnosed population and supports future procedure growth.

Countries such as the United Kingdom are increasing screening efforts partly because aneurysm prevalence is expected to rise with aging populations. As more patients are diagnosed, more will enter treatment pathways where stent grafts are considered. This makes screening a meaningful long-term driver for the market.

Market Limiters

Difficult Anatomy

The most important limiter in the global stent graft market is difficult anatomy. The success of a stent graft procedure depends heavily on careful imaging, precise sizing and the match between device design and patient anatomy. Not every patient is anatomically suitable for standard abdominal or thoracic endovascular repair.

Irregular neck anatomy, vessel tortuosity, branch involvement and other structural challenges can limit the feasibility of stent graft procedures. Although modular graft systems and newer fenestrated and branched designs have expanded the number of treatable patients, a meaningful portion of patients still require open surgical repair because endovascular treatment is not anatomically viable or because rupture risk does not allow the time needed for more customized approaches.

This limitation is especially important because it creates a ceiling on how much the market can grow through standard devices alone. Innovation continues to push that ceiling higher, but anatomy remains a central constraint.

Stent Graft Complications

Stent graft complications also continue to limit the market. Compared with open surgery, endovascular aneurysm repair can carry a higher risk of reintervention over the long term. Certain trials, including the DREAM trial, highlighted that EVAR was associated with higher reintervention rates, which has influenced physician thinking and long-term follow-up practices.

There is also concern around aneurysm rupture risk after stent graft placement, particularly if sealing is incomplete or if long-term device performance is compromised. These concerns do not eliminate the appeal of stent grafts, but they do make follow-up imaging and surveillance more important. In some health systems, this can reduce the simplicity of the economic case and influence how physicians select patients.

Complexity of Advanced Cases

A further limiter is the complexity of advanced stent graft cases. Fenestrated and thoracic procedures can offer strong clinical value, but they also require greater procedural planning, more specialized imaging and more technical expertise. This can limit adoption to higher-volume centers or more experienced operators, especially in regions where advanced endovascular infrastructure is less developed.

As a result, market growth in advanced segments may be strong, but not evenly distributed. Adoption depends not only on clinical need, but also on physician training and center capability.

Market Coverage and Data Scope

Quantitative Coverage

Market size, market shares, market forecasts, market growth rates, units sold and average selling prices.

Qualitative Coverage

Market drivers and limiters, growth trends, recent mergers and acquisitions, company profiles, product portfolios and leading competitors.

Time Frame

Base year 2025, historical data to 2022 and forecasts through 2032.

Regional Coverage

North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Asia-Pacific and Africa.

Data Types Included

Unit sales, average selling prices, procedure numbers, market size and growth trends.

This report is designed to support strategic planning, competitor benchmarking and product positioning by combining detailed forecasting with practical clinical and commercial context.

Markets Covered and Segmentation

• The report covers the Global Stent Graft Market, further segmented into:

AAA Stent Graft Market

This segment includes devices used in abdominal aortic aneurysm repair, including major component categories used in standard EVAR procedures.

Fenestrated Stent Graft Market

This segment includes advanced graft systems designed for more complex anatomies where branch vessel preservation and customized sealing are important.

TAA Stent Graft Market

This segment includes thoracic aortic aneurysm stent grafts used in TEVAR procedures and other thoracic aortic interventions.

Each segment is analyzed by unit sales, average selling prices and total market value, with forecasts through 2032 and historical data to 2022. This segmentation reflects the major clinical use areas in which endovascular graft technology continues to expand.

Competitive Analysis

W.L. Gore holds a leading position across multiple segments of the abdominal aortic aneurysm market, including bifurcated main body grafts, contralateral and ipsilateral iliac legs or limbs, and iliac extensions. It also holds a strong second-place position in aortic extension segments. Although the company does not offer an aorto-uni-iliac stent graft, its broader AAA portfolio remains highly influential. Regulatory milestones have also supported its position. The GORE EXCLUDER Iliac Branch System received FDA approval in 2016, while the GORE TAG Thoracic Branch Endoprosthesis received FDA approval in 2022 for high-risk patients requiring left subclavian artery debranching procedures. Gore also received approval for the TAG Conformable thoracic stent system with ACTIVE CONTROL, which supports improved deployment control and sealing in TEVAR.

Medtronic remains one of the most important global competitors through its Endurant II AAA portfolio and its Valiant thoracic stent graft family. In the thoracic segment, Medtronic positions Valiant at a premium price level relative to several competitors. The company strengthened its EVAR and TEVAR position through investment in Arsenal AAA and its acquisition of Aptus Endosystems, which added the Heli-FX and Heli-FX Thoracic EndoAnchor systems. Medtronic also received FDA approval for the Valiant Navion thoracic stent graft system and later expanded the Valiant family into thoracoabdominal use, helping reinforce its role in advanced aortic repair.

Cook Medical remains a major competitor with a broad AAA and thoracic portfolio. Its Zenith Flex and Zenith Renu families give it meaningful presence across standard abdominal components, and the company is especially notable in the fenestrated segment through the Zenith Fenestrated line. That offering has supported strong revenue growth over time, although adoption can be limited by assessment complexity, longer wait times and higher cost. In thoracic repair, Cook markets the Zenith Alpha family, which received FDA approval for isolated descending thoracic aorta lesions. Cook's relatively low per-case ASP also shapes its market position, especially where pricing remains important.

Overall, the competitive landscape is shaped by product breadth, regulatory progress, anatomical reach and the ability to support increasingly complex endovascular repair.

Technology and Practice Trends

A major trend in the global stent graft market is the continued move toward minimally invasive aortic repair. Physicians increasingly prefer endovascular approaches when patient anatomy and clinical condition permit.

Another important trend is the development of more advanced stent graft technologies. Lower-profile devices, improved flexibility, better trackability and more specialized branch and fenestrated systems are making treatment possible in a broader set of anatomies.

Imaging and navigation are also becoming more important. Better pre-procedural planning and more precise deployment support improved outcomes and can reduce complications and reintervention risk.

Finally, the market is moving toward more anatomically tailored treatment. Standard devices remain important, but growth is increasingly supported by more specialized stent graft designs that address complex anatomy and high-risk patient subsets.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

109 pages of detailed market analysis, regional discussion and forecast data.

Methodology Appendix and Acronym Glossary.

Why This Report

Where are the largest and fastest-growing opportunities in the global stent graft market through 2032?

How are thoracic and fenestrated technologies changing the value mix of the market?

What role do screening programs and minimally invasive treatment preferences play in future growth?

How do difficult anatomy and reintervention risk limit the total addressable market for stent grafts?

Which companies hold the strongest positions in AAA, fenestrated and TAA stent grafts, and how are they competing?

How can suppliers align product strategy with the growing need for more precise and more anatomically flexible endovascular repair?

The Global Stent Graft Market Report from iData Research answers these questions with detailed segmentation, pricing analysis, competitive intelligence and market forecasting. Use it to benchmark competitors, evaluate growth opportunities and support strategy in one of the most important vascular intervention device categories.

TABLE OF CONTENT

List Of Figures

List Of Charts

Research Methodology

• Step 1: Project Initiation & Team Selection
• Step 2: Prepare Data Systems And Perform Secondary Research
• Step 3: Preparation For Interviews & Questionnaire Design
• Step 4: Performing Primary Research
• Step 5: Research Analysis: Establishing Baseline Estimates
• Step 6: Market Forecast And Analysis
• Step 7: Identify Strategic Opportunities
• Step 8: Final Review And Market Release
• Step 9: Customer Feedback And Market Monitoring

Impact Of Global Tariffs

Stent Graft Market

• 11.1 Executive Summary
  • 11.1.1 Global Stent Graft Market Overview
  • 11.1.2 Competitive Analysis
  • 11.1.3 Procedures Included
  • 11.1.4 Markets Included
  • 11.1.5 Regions Included
• 11.2 Introduction
• 11.3 Procedure Numbers
  • 11.3.1 Total Stent Graft Procedures
  • 11.3.2 Aaa Stent Graft Procedures
  • 11.3.3 Fenestrated Stent Graft Procedures
  • 11.3.4 Taa Stent Graft Procedures
• 11.4 Market Overview
  • 11.4.1 By Segment
  • 11.4.2 By Region
• 11.5 Market Analysis And Forecast
  • 11.5.1 Total Stent Graft Market
  • 11.5.2 Aaa Stent Graft Market
  • 11.5.3 Fenestrated Stent Graft Market
  • 11.5.4 Taa Stent Graft Market
• 11.6 Drivers And Limiters
  • 11.6.1 Market Drivers
  • 11.6.2 Market Limiters
• 11.7 Competitive Market Share Analysis

Abbreviations

LIST OF CHARTS

• Chart 11-1: Stent Graft Market, Global, 2025 & 2032
• Chart 11-2: Stent Graft Procedures, Global, 2025
• Chart 11-3: Stent Graft Procedures by Segment, Global, 2022 - 2032
• Chart 11-4: Stent Graft Market by Segment, Global, 2022 - 2032
• Chart 11-5: Stent Graft Market by Region, Global, 2022 - 2032
• Chart 11-6: Leading Competitors, Stent Graft Market, Global, 2025

LIST OF FIGURES

• Figure 11-1: Stent Graft Procedures Covered
• Figure 11-2: Stent Graft Markets Covered
• Figure 11-3: Stent Graft Regions Covered, Global (1 of 2)
• Figure 11-4: Stent Graft Regions Covered, Global (2 of 2)
• Figure 11-5: Stent Graft Procedures by Segment, Global, 2022 - 2032
• Figure 11-6: Stent Graft Procedures by Region, Global, 2022 - 2032
• Figure 11-7: Stent Graft Procedures by Country, North America, 2022 - 2032
• Figure 11-8: Stent Graft Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 11-9: Stent Graft Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 11-10: Stent Graft Procedures by Country, Western Europe, 2022 - 2032
• Figure 11-11: Stent Graft Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 11-12: Stent Graft Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 11-13: Stent Graft Procedures by Country, Middle East, 2022 - 2032
• Figure 11-14: Stent Graft Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 11-15: Stent Graft Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 11-16: Stent Graft Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 11-17: Stent Graft Procedures by Country, Africa, 2022 - 2032
• Figure 11-18: AAA Stent Graft Procedures by Region, Global, 2022 - 2032
• Figure 11-19: AAA Stent Graft Procedures by Country, North America, 2022 - 2032
• Figure 11-20: AAA Stent Graft Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 11-21: AAA Stent Graft Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 11-22: AAA Stent Graft Procedures by Country, Western Europe, 2022 - 2032
• Figure 11-23: AAA Stent Graft Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 11-24: AAA Stent Graft Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 11-25: AAA Stent Graft Procedures by Country, Middle East, 2022 - 2032
• Figure 11-26: AAA Stent Graft Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 11-27: AAA Stent Graft Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 11-28: AAA Stent Graft Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 11-29: AAA Stent Graft Procedures by Country, Africa, 2022 - 2032
• Figure 11-30: Fenestrated Stent Graft Procedures by Region, Global, 2022 - 2032
• Figure 11-31: Fenestrated Stent Graft Procedures by Country, North America, 2022 - 2032
• Figure 11-32: Fenestrated Stent Graft Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 11-33: Fenestrated Stent Graft Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 11-34: Fenestrated Stent Graft Procedures by Country, Western Europe, 2022 - 2032
• Figure 11-35: Fenestrated Stent Graft Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 11-36: Fenestrated Stent Graft Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 11-37: Fenestrated Stent Graft Procedures by Country, Middle East, 2022 - 2032
• Figure 11-38: Fenestrated Stent Graft Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 11-39: Fenestrated Stent Graft Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 11-40: Fenestrated Stent Graft Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 11-41: Fenestrated Stent Graft Procedures by Country, Africa, 2022 - 2032
• Figure 11-42: TAA Stent Graft Procedures by Region, Global, 2022 - 2032
• Figure 11-43: TAA Stent Graft Procedures by Country, North America, 2022 - 2032
• Figure 11-44: TAA Stent Graft Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 11-45: TAA Stent Graft Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 11-46: TAA Stent Graft Procedures by Country, Western Europe, 2022 - 2032
• Figure 11-47: TAA Stent Graft Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 11-48: TAA Stent Graft Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 11-49: TAA Stent Graft Procedures by Country, Middle East, 2022 - 2032
• Figure 11-50: TAA Stent Graft Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 11-51: TAA Stent Graft Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 11-52: TAA Stent Graft Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 11-53: TAA Stent Graft Procedures by Country, Africa, 2022 - 2032
• Figure 11-54: Stent Graft Market by Segment, Global, 2022 - 2032 (US$M)
• Figure 11-55: Stent Graft Market by Region, Global, 2022 - 2032 (US$M)
• Figure 11-56: Stent Graft Market, Global, 2022 - 2032
• Figure 11-57: Units Sold by Region, Stent Graft Market, Global, 2022 - 2032
• Figure 11-58: Average Selling Price by Region, Stent Graft Market, Global, 2022 - 2032 (US$)
• Figure 11-59: Market Value by Region, Stent Graft Market, Global, 2022 - 2032 (US$M)
• Figure 11-60: AAA Stent Graft Market, Global, 2022 - 2032
• Figure 11-61: Units Sold by Region, AAA Stent Graft Market, Global, 2022 - 2032
• Figure 11-62: Average Selling Price by Region, AAA Stent Graft Market, Global, 2022 - 2032 (US$)
• Figure 11-63: Market Value by Region, AAA Stent Graft Market, Global, 2022 - 2032 (US$M)
• Figure 11-64: Fenestrated Stent Graft Market, Global, 2022 - 2032
• Figure 11-65: Units Sold by Region, Fenestrated Stent Graft Market, Global, 2022 - 2032
• Figure 11-66: Average Selling Price by Region, Fenestrated Stent Graft Market, Global, 2022 - 2032 (US$)
• Figure 11-67: Market Value by Region, Fenestrated Stent Graft Market, Global, 2022 - 2032 (US$M)
• Figure 11-68: TAA Stent Graft Market, Global, 2022 - 2032
• Figure 11-69: Units Sold by Region, TAA Stent Graft Market, Global, 2022 - 2032
• Figure 11-70: Average Selling Price by Region, TAA Stent Graft Market, Global, 2022 - 2032 (US$)
• Figure 11-71: Market Value by Region, TAA Stent Graft Market, Global, 2022 - 2032 (US$M)
• Figure 11-72: Leading Competitors, Stent Graft Market, Global, 2025